You are viewing a preview of...

A Designer Probiotic-Based Intervention to Prevent Infection

This technology is a Lactobacillus system that serves as a vaccine platform with the potential to develop COVID-19 therapeutics


Clostridium difficile is the leading cause of healthcare-associated diarrheas worldwide. Clostridium difficile has been associated with increased mortality and relapsing diseases in the past fifteen years. There is currently no treatment for C. difficile outside of antibiotics. Consumers are becoming more educated and health conscious. The US probiotics market was estimated to be $97.5 million in 2000 and the annual growth rate is estimated to be 7 percent. Consumers are purchasing more dietary supplements to prevent diseases. These are all major factors for growth in the probiotics market.

While this invention was originally created to address C. difficile, it has the potential to develop COVID‑19 therapeutics.

Log in or create a free account to continue reading